- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01254877
Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons
Ondansetron Pharmacotherapy for Hazardous Drinking in HIV+, African-American Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hazardous drinking is particularly harmful in HIV-infected persons. It impairs the immune system, accelerates HIV disease progression, slows initiation of antiretroviral therapy (ART) and decreases adherence. Thus, the development of effective alcohol treatments for this clinical population is particularly important. The investigators are proposing to investigate the effectiveness of ondansetron pharmacotherapy for the treatment of hazardous alcohol use and alcohol abuse/dependence among HIV-infected patients. Ondansetron, a 5-HT3 antagonist, will be studied for several reasons: 1) evidence of effectiveness in persons who want to cut-down or reduce their drinking and who are not abstinent at medication initiation; 2) moderate-to-strong effects among early onset problem drinkers, a characteristic that is over represented in our clinic patients; 3) a very mild side-effect profile, making it an ideal pharmacotherapy candidate in patients who are often receiving multiple other medications with significant side-effects; and 4) its primary indication is for treatment of nausea, a common side-effect of antiretroviral (ARV) medications.
The proposed study is a placebo-controlled, randomized clinical trial of ondansetron for the treatment of hazardous drinking and alcohol use disorders among HIV-infected patients recruited from the Baltimore/Washington area. Participants will be genotyped for a functional polymorphism of the serotonin transporter gene. They will be randomized to one of three treatment groups: placebo, low dose ondansetron (0.2 mg bid) and moderate dose ondansetron (0.8 mg bid). All subjects will undergo 16 weeks of pharmacotherapy in combination with medication management, and will be followed for 3 and 6 months after medication has ended.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects will be at least 18 years old and HIV-infected
- All subjects will be actively drinking at hazardous levels (1) AUDIT score => 4 for women or =>8 for men, or 2) => 2 binge drinking episodes/month, or 3) >7 drinks/week for women or >14 drinks/week for men)
Exclusion Criteria:
- Liver Function Tests (LFTs) > 5 X normal
- Magnesium or potassium > 3 X normal
- Qtc => .460 and or a family history of long QT syndrome (LQT)
- Inability to read and comprehend English
- Actively psychotic or other severe mental health symptoms that would prevent appropriate participation
- Current enrollment in alcoholism treatment program
- Pregnancy; Ondansetron is currently a category B drug. While animal data have not identified any harmful effects to mother or fetus, there have not been adequate human controlled trials to recommend routine use in this population
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Ondansetron - sugar pill
Placebo is an oral preparation made to appear and taste like the active drug preparation.
|
Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
|
Experimental: low dose ondansetron (0.2 mg bid)
|
ondansetron 0.2 mg bid, oral preparation, 16 weeks
|
Experimental: moderate dose ondansetron (0.8 mg bid)
|
Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Alcoholic Containing Drinks Per Drinking Day
Time Frame: 16 weeks
|
The Time-line Follow-back (TLFB; Sobell, Sobell, Leo & Cancilla, 1988) is conducted as an interview administered by trained and certified research staff.
The interview obtains participant self-reports of daily drinking, including number and type of alcoholic beverages.
These data are used to quantify an individual's drinking pattern including the number of drinks per drinking day and drinking frequency.
The TLFB was completed biweekly and quantified over the 16-week medication period
|
16 weeks
|
Number of Days/Week Abstinent From Alcohol
Time Frame: 16 weeks
|
The Time-line Follow-back (Sobell, Sobell, Leo & Cancilla, 1988) is used to obtain this secondary dependent measure.
Alcohol use will be assessed biweekly and quantified over the 16-week medication period.
Number of days/week abstinent from alcohol is calculated as the number of abstinent days divided by the number of study medication days (adjusted for days in confinement (e.g., hospitalization; jail)) and multiplied by 7.
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication Safety
Time Frame: 16 weeks
|
Medication side-effects and adverse events were measured using the Systematic Assessment for Treatment of Emergent Events (SAFTEE).
The SAFTEE contains 25 detailed questions that systematically address 29 body systems.
A trained interviewer elicits information about onset, duration, pattern, and judgment of attribution.
For the present trial outcome, we report number of events.
|
16 weeks
|
Number of Subjects Who Discontinue Due to Side Effects
Time Frame: 16 weeks
|
The investigators will count the number of subjects who discontinue medication during the 16-week intervention period due to complaints of side effects.
|
16 weeks
|
Alcohol-related Problems
Time Frame: 16 weeks
|
Alcohol-related problems were measured using the Short Inventory of Problems - revised (SIP-R), a self-report inventory of adverse consequences associated with alcohol and drug use.
The SIP instructs participants to indicate how often each of 15 consequences has occurred during the past three months ("never," "once or a few times," "once or twice a week," "daily or almost daily"; scored 0-3).
Item responses are summed to produce a total score and five subscale scores.
Total scores range from 0 - 45.
|
16 weeks
|
HIV Medication Adherence
Time Frame: 16 weeks
|
The investigators will obtain patient self reports of the number of HIV medication doses taken as a function of the total number of doses prescribed.
The adherence measure is expressed as the % of prescribed doses.
|
16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mary E McCaul, Ph.D., Johns Hopkins University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Alcohol-Related Disorders
- Substance-Related Disorders
- Alcoholism
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Antagonists
- Anti-Anxiety Agents
- Antipruritics
- Ondansetron
Other Study ID Numbers
- NA_00032774
- R01AA018896 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Dependence
-
University Hospital, LilleCompleted
-
Tel-Aviv Sourasky Medical CenterMinistry of Health, IsraelUnknownAlcohol-dependenceIsrael
-
Pop Test Oncology LLCBaylor College of Medicine; Michael E. DeBakey VA Medical Center; Congressionally... and other collaboratorsCompletedPotential Treatment for Alcohol Dependence-Alcohol InteractionUnited States
-
DynamiCare HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA); RANDActive, not recruitingAlcohol Dependence | Alcohol Use Disorder | Drug DependenceUnited States
-
National Institute on Alcohol Abuse and Alcoholism...CompletedAlcohol Abuse | Alcohol Dependence (Primary Condition)United States
-
University Hospital, Gentofte, CopenhagenCompleted
-
Massachusetts General HospitalCompletedAlcohol Dependence | Drug Abuse | Alcohol Abuse | Drug DependenceUnited States
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
University of WashingtonU.S. Army Medical Research and Development CommandCompletedAlcohol Dependence | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
Clinical Trials on placebo ondansetron
-
University of Colorado, DenverNational Institute of Mental Health (NIMH)CompletedSchizophreniaUnited States
-
Washington University School of MedicineCompleted
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting
-
Seoul National University Bundang HospitalRecruiting
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingDiabetes Mellitus | IndigestionUnited States
-
Tanta UniversityRecruitingCaesarean Section | Postoperative Nausea and Vomiting | Ondansetron LozengeEgypt
-
University of PittsburghMerck Sharp & Dohme LLCCompletedPostoperative Nausea and VomitingUnited States
-
Halozyme TherapeuticsCompleted
-
TakedaCompletedPostoperative Nausea and Vomiting (PONV)United States